Literature DB >> 8645579

Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus.

F Basolo1, L Fiore, S Calvo, V Falcone, P G Conaldi, G Fontanini, A M Caligo, G Merlo, Y Gluzman, A Toniolo.   

Abstract

Mammary epithelial cells (MECs) were isolated and cultured from mammary glands of healthy women undergoing reduction mammoplasty. Normal MECs were infected with the transforming hybrid virus adeno-5/SV40. Two transformed epithelial cell lines, M1 and M2, were obtained, characterised phenotypically and studied for the production of and the response to cytokines and growth regulators. In both cell lines, expression of the SV40 large T antigen was associated with loss of interleukin 6 (IL-6) production and responsiveness as well as with down-regulation of IL-8 and transforming growth factor (TGF)-alpha production. Both M1 and M2 cell lines were capable of forming colonies in semisolid media, but upon injection into severe combined immunodeficient (SCID) mice only M2 cells were tumorigenic. DNA synthesis in M1 cells was partially inhibited by serum or TNF-alpha and weakly stimulated by hydrocortisone (HC) and IL-8. In contrast, M2 cells were totally unresponsive to a variety of growth regulators. Both lines overexpressed the p53 protein at levels about 20-fold higher than those observed in primary MEC cultures, but no mutations of the p53 gene could be detected. The date confirm the view that the expression in human mammary cells of different oncogenes - including the SV40 T antigen - is frequently associated with alterations of cytokine production and responsiveness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645579      PMCID: PMC2074491          DOI: 10.1038/bjc.1996.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Characterization of epithelial phenotypes in mortal and immortal human breast cells.

Authors:  T M Paine; H D Soule; R J Pauley; P J Dawson
Journal:  Int J Cancer       Date:  1992-02-01       Impact factor: 7.396

2.  Increased invasive, chemotactic and locomotive abilities of c-Ha-ras-transformed human breast epithelial cells.

Authors:  J Ochieng; F Basolo; A Albini; A Melchiori; H Watanabe; J Elliott; A Raz; S Parodi; J Russo
Journal:  Invasion Metastasis       Date:  1991

3.  Expression and stability of p53 protein in normal human mammary epithelial cells.

Authors:  L Delmolino; H Band; V Band
Journal:  Carcinogenesis       Date:  1993-05       Impact factor: 4.944

4.  p53 mutations in human immortalized epithelial cell lines.

Authors:  T A Lehman; R Modali; P Boukamp; J Stanek; W P Bennett; J A Welsh; R A Metcalf; M R Stampfer; N Fusenig; E M Rogan
Journal:  Carcinogenesis       Date:  1993-05       Impact factor: 4.944

5.  Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus.

Authors:  J Bartek; J Bartkova; N Kyprianou; E N Lalani; Z Staskova; M Shearer; S Chang; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

6.  Regulation of surface-differentiation molecules by epidermal growth factor, transforming growth factor alpha, and hydrocortisone in human mammary epithelial cells transformed by an activated c-Ha-ras proto-oncogene.

Authors:  F Basolo; C Serra; F Ciardiello; L Fiore; J Russo; D Campani; A Dolei; F Squartini; A Toniolo
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

7.  Growth-stimulating activity of interleukin 6 on human mammary epithelial cells transfected with the int-2 gene.

Authors:  F Basolo; S Calvo; L Fiore; P G Conaldi; V Falcone; A Toniolo
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Studies of clonal cell lines developed from primary breast cancers indicate that the ability to undergo morphogenesis in vitro is lost early in malignancy.

Authors:  M Shearer; J Bartkova; J Bartek; F Berdichevsky; D Barnes; R Millis; J Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

9.  Single-steep transformation of human breast epithelial cells by SV40 large T oncogene.

Authors:  P Berthon; G Goubin; B Dutrillaux; A Degeorges; A Faille; C Gespach; F Calvo
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

10.  Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium.

Authors:  J Taylor-Papadimitriou; M Stampfer; J Bartek; A Lewis; M Boshell; E B Lane; I M Leigh
Journal:  J Cell Sci       Date:  1989-11       Impact factor: 5.285

View more
  5 in total

Review 1.  Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens.

Authors:  U Moens; O M Seternes; B Johansen; O P Rekvig
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

Review 2.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

3.  Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes.

Authors:  Alessia A Bettaccini; Andreina Baj; Roberto S Accolla; Fulvio Basolo; Antonio Q Toniolo
Journal:  BMC Microbiol       Date:  2005-04-27       Impact factor: 3.605

4.  Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.

Authors:  G Fontanini; D Campani; M Roncella; D Cecchetti; S Calvo; A Toniolo; F Basolo
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 5.  Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development.

Authors:  Valérie Gouon-Evans; Elaine Y Lin; Jeffrey W Pollard
Journal:  Breast Cancer Res       Date:  2002-06-25       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.